ToTheMOON
2021-12-01
Thirty days later than yesterday lol
Regeneron's COVID-19 antibody drug may be less effective against Omicron
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603962112,"tweetId":"603962112","gmtCreate":1638353740423,"gmtModify":1638353741190,"author":{"id":3576212227172632,"idStr":"3576212227172632","authorId":3576212227172632,"authorIdStr":"3576212227172632","name":"ToTheMOON","avatar":"https://static.tigerbbs.com/7769f4b8d26aa1903d8784e79b05b4df","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":47,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Thirty days later than yesterday lol </p></body></html>","htmlText":"<html><head></head><body><p>Thirty days later than yesterday lol </p></body></html>","text":"Thirty days later than yesterday lol","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603962112","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","kind":"news","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8 <a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","MRNA":"Moderna, Inc.","GILD":"吉利德科学"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603962112"}
精彩评论